A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of Cvx-096 In Type 2 Diabetic Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2017
At a glance
- Drugs PF 4856883 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Pfizer
- 22 Jul 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Mar 2011 Planned end date changed from 1 Jul 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.